PMID- 9394775
OWN - NLM
STAT- MEDLINE
DCOM- 19971224
LR  - 20190707
IS  - 0016-5085 (Print)
IS  - 0016-5085 (Linking)
VI  - 113
IP  - 6 Suppl
DP  - 1997 Dec
TI  - What other regimens are under investigation to treat Helicobacter pylori 
      infection?
PG  - S131-48
AB  - The most common infection in the world, Helicobacter pylori infection, is very 
      specific, and present experience in treating infectious diseases is not 
      applicable in general for this infection. Animal models (e.g., mouse and ferret) 
      are thus far inadequate as reliable screening models. Old-fashioned 
      trial-and-error treatment of infected humans is still the screening model and the 
      gold standard in the evaluation of regimens aimed at eradication of H. pylori. A 
      variety of studies on treatment of H. pylori infection have been performed with 
      varying results. This pooled analysis of the following therapeutic combinations: 
      proton pump inhibitor (PPI) plus two antibiotics or antimicrobials, quadruple 
      therapies, and nonantibiotic regimens is an attempt to make a fair comparison of 
      tested therapeutic strategies aimed at eradicating H. pylori. Data from treatment 
      groups including specified drug combinations are pooled, regardless of dose or 
      duration. Search methods are: MEDLINE 1984-1996, Digestive Disease Week 
      1988-1996, United European Gastroenterology Week 1992-1996, European Helicobacter 
      pylori Study Group 1988-1996, Asia Pacific Congress 1996, H. pylori International 
      Workshop Hong Kong 1996, and miscellaneous. Eradication rates (efficacy) are 
      presented as intention-to-treat data (i.e., worst-case analysis). Separate 
      subanalyses with regard to study quality, dose, and duration are performed for 
      some groups. A general cost-efficacy analysis is performed based on pooled 
      efficacy data. Convenience data are presented as total number of tablets, total 
      number of intake occasions, and duration of therapy. Drugs evaluated in the 
      analysis are bismuthdicitrate, tetracycline, amoxicillin, nitroimidazoles, 
      macrolides, H2-receptor antagonists, PPIs, sucralfate, and sofalcone. The most 
      effective and convenient drug combinations are the PPI-based triple therapies. No 
      significant difference was observed between the three PPIs. The cure rate did not 
      improve after addition of bismuth. Cost-effectiveness is closely associated with 
      efficacy.
FAU - Unge, P
AU  - Unge P
AD  - Department of Medicine, Lanssjukhuset Gavle Sandviken, Sweden.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Anti-Bacterial Agents/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Helicobacter Infections/*drug therapy
MH  - *Helicobacter pylori
MH  - Humans
MH  - Randomized Controlled Trials as Topic
RF  - 378
EDAT- 1997/12/12 00:00
MHDA- 1997/12/12 00:01
CRDT- 1997/12/12 00:00
PHST- 1997/12/12 00:00 [pubmed]
PHST- 1997/12/12 00:01 [medline]
PHST- 1997/12/12 00:00 [entrez]
AID - S0016508597005854 [pii]
AID - 10.1016/s0016-5085(97)80027-3 [doi]
PST - ppublish
SO  - Gastroenterology. 1997 Dec;113(6 Suppl):S131-48. doi: 
      10.1016/s0016-5085(97)80027-3.